Wongcharoen Wanwarang, Chen Shih-Ann
Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Expert Rev Cardiovasc Ther. 2009 Mar;7(3):311-22. doi: 10.1586/14779072.7.3.311.
Atrial fibrillation (AF) and heart failure are the two modern epidemics of cardiovascular disease. They are commonly encountered together and either condition predisposes to the other. Patients with both AF and heart failure carry a poor prognosis; therefore, the management of this group of patients should be addressed aggressively. In the context of AF management in patients with heart failure, the pharmacologic rhythm control strategy is not superior to the rate control strategy. Due to the adverse effects of anti-arrhythmic agents, the rate control should be considered as a primary approach. The long-term data regarding the efficacy and safety of catheter-based ablation therapy in the patients with heart failure are limited; hence, the catheter ablation of AF should be reserved for the patients for whom the drug therapy is inadequate or undesirable. Ultimately, the patient's symptoms and the tolerance for the particular treatment should be taken into account for the management of AF in patients with heart failure.
心房颤动(AF)和心力衰竭是心血管疾病的两大现代流行病。它们经常同时出现,且任何一种情况都易引发另一种情况。同时患有AF和心力衰竭的患者预后较差;因此,应对这组患者进行积极治疗。在心力衰竭患者的AF管理方面,药物节律控制策略并不优于心率控制策略。由于抗心律失常药物的不良反应,应将心率控制视为主要方法。关于基于导管的消融治疗在心力衰竭患者中的疗效和安全性的长期数据有限;因此,AF导管消融应仅用于药物治疗不足或不理想的患者。最终,在管理心力衰竭患者的AF时,应考虑患者的症状和对特定治疗的耐受性。